- Recruiting
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
Updated: Sep 29, 2022
Talquetamab Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed & Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
TALMMY1001-Part 3
The corresponding study (NCT03399799) is the Phase 1 part of the study and TALMMY1001- Part 3 is the Phase 2 part of the study.
Sponsor
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT04634552
Official Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
First Posted : November 18, 2020
Click here to see details on ClinicalTrials.gov
Drug: Talquetamab
bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D)
JNJ 64407564
- Arkansas: University of Arkansas Little Rock
- Alabama: University of Alabama at Birmingham
- California: City of Hope Duarte
- Georgia: Emory University Atlanta
- Illinois: University of Chicago
- Missouri: Washington University School of Medicine Saint Louis
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New York: NYU Langone Medical Center New York
- New York: University of Rochester New York
- North Carolina: Levine Cancer Institute Charlotte
- Tennessee: Sarah Cannon Research Institute Nashville
Locations
United States, Alabama
United States, Arizona
United States, Arkansas
United States, California
United States, Georgia
United States, Illinois
United States, Kentucky
United States, Michigan
United States, Missouri
United States, New York
United States, North Carolina
United States, Ohio
United States, Oregon
United States, Tennessee
United States, Texas
Europe
France
Germany
Netherlands
Spain
Belgium
Poland
Asia
Israel
Japan
Korea, Republic of
China
RELATED POSTS
TECLISTAMAB STUDIES:
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)
NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
TALQUETAMAB STUDIES:
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
TECLISTAMAB AND TALQUETAMAB STUDIES:
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2